Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Skye Bioscience Inc SKYE

Healthcare Biotechnology
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation... see more

Recent & Breaking News (NDAQ:SKYE)

Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Second Patent Issued in the United States Related to Proprietary Delivery Mechanisms for Treatment of Glaucoma

Marketwired May 9, 2017

Nemus Bioscience Announces $20 Million Series E Preferred Stock Financing

Marketwired May 4, 2017

NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

Marketwired March 22, 2017

Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)

Marketwired March 20, 2017

NEMUS Bioscience and Catalent to Advance NB1222 into Human Dosage Formulation Development

Marketwired March 3, 2017

Nemus Bioscience Reports Favorable Bio-distribution and Anti-Addictive Findings Versus Plant-Derived Cannabidiol (CBD) in Animal Model Studies of NB2111, an Analogue of Cannabidiol

Accesswire February 13, 2017

Nemus Bioscience Announces Advancement of Analgesic Program Utilizing NB2111, an Analogue of Cannabidiol; Approaches Pain Management with a "Continuum of Care" Strategy

Accesswire January 31, 2017

Nemus Bioscience Announces Licensing Agreement with the University of Mississippi (UM) for a Cannabinoid-Based Anti-infective Platform Directed Against Drug-Resistant Organisms

Accesswire January 11, 2017

NEMUS Bioscience Announces Closing of $1,200,000 Preferred Stock Financing

Accesswire January 10, 2017

Nemus Bioscience Announces Preferred Stock Financing

Accesswire December 29, 2016

Nemus Bioscience Announces License of Biosynthetic Technology from Teewinot Life Sciences to Manufacture its Proprietary Cannabinoid Molecules

Accesswire December 20, 2016

Nemus Bioscience Announces Analog of Cannabidiol (CBD) Achieves Multi-Chamber Ocular Penetration in Animal Model Using Initial Ophthalmic Formulation

Accesswire December 14, 2016

Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Intellectual Property Protection in the European Union (E.U.) and Australia Following Patents issued in the United States and Japan

Accesswire December 12, 2016

Nemus Bioscience Announces Milestones in the Development of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient (API) for Drug Candidates NB1111 and NB2111 and Formulation Contract with AMRI and Catalent Pharma Solutions

Accesswire December 1, 2016

Cannabinoid Drug Advancements Take Off After Quantum Shift in U.S. Drug Policy

PR Newswire November 16, 2016

Nemus Bioscience Announces Presentation of NB1111 Impact on Intraocular Pressure (IOP) in Normotensive Ocular Model at the National Meeting of the American Association of Pharmaceutical Scientists (AAPS)

Accesswire November 15, 2016

NEMUS Bioscience Announces Closing of $500,000 Preferred Stock Financing

Accesswire October 27, 2016

NEMUS Bioscience Announces $500,000 Preferred Stock Financing

Accesswire October 26, 2016

NEMUS Bioscience, Inc. to Attend Upcoming Investment Conferences

Marketwired September 7, 2016

Nemus Bioscience Announces Enhanced Ocular Tissue Concentration by the Proprietary Prodrug of Tetrahydrocannabinol (NB1111) - Associated With a Superior Decline in Intra-Ocular Pressure (IOP) in an Animal Model

Marketwired June 16, 2016